Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Veracyte announced positive results from the Phase III OPTIMA trial for its Prosigna breast cancer test, demonstrating that 68% of high-risk patients could safely avoid chemotherapy without compromising outcomes. The study showed 5-year cancer-free survival of 93.7% for patients omitting chemotherapy versus 94.9% for those receiving it, confirming non-inferiority in a broad population including premenopausal women and those with extensive nodal involvement.
Key figures
- Drug Name
- Prosigna
- Phase Of Trial
- Phase III
- Trial patients
- 4429
- Median follow up years
- 4
- Patients sparing chemo pct
- 68%
- 5yr cancer free survival chemo
- 94.9%
- 5yr cancer free survival no chemo
- 93.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.